AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22491538 — intervention group
Group type: EXPERIMENTAL
Intervention: Air transport
Number of subjects: 2049
Study 22491538 — intervention group
Group type: COMPARATOR
Intervention: Ground transport
Number of subjects: 2049
Study 20222892 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine (TRESIVAC(R)) containing Leningrad-Zagreb mumps strain
Number of subjects: 453119
Study 20222892 — intervention group
Group type: COMPARATOR
Intervention: Control group (younger children)
Number of subjects: 453119
Study 17079694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus Irinotecan (IP)
Number of subjects: 602
Study 17079694 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus Paclitaxel (TC)
Number of subjects: 602
Study 17079694 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus Gemcitabine (GP)
Number of subjects: 602
Study 17079694 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus Vinorelbine (NP)
Number of subjects: 602
Study 16305592 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 10
Study 12152000 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide 45 mg (subcutaneous)
Number of subjects: 12
Study 12152000 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide 90 mg (subcutaneous)
Number of subjects: 12
Study 12152000 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide 180 mg (subcutaneous)
Number of subjects: 12
Study 12152000 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide 90 mg (intravenous)
Number of subjects: 12
Study 10202343 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP; 800 microg/day)
Number of subjects: 14
Study 10202343 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beta2‐agonists alone
Number of subjects: 14
Study 8525222 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer multimedia program (independent study program on hypertension)
Number of subjects: 100
Study 8525222 — intervention group
Group type: COMPARATOR
Intervention: Classical lectures (control group)
Number of subjects: 100
Study 2203251 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet (total fat intake reduced from 37% to 21% of calories, carbohydrate intake increased from 44% to 52% of calories)
Number of subjects: 0
Study 2203251 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet
Number of subjects: 0
Study 11086 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (4 X 200 mg/d p.o.)
Number of subjects: 12
Study 11086 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 12
Study 31274363 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-hour resiliency program
Number of subjects: 32
Study 31274363 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 27203734 — intervention group
Group type: EXPERIMENTAL
Intervention: VONCENTO (plasma-derived VWF/FVIII concentrate)
Number of subjects: 21
Study 25371035 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT; 3‐min intervals at 40% and 80% V̇O2max)
Number of subjects: 60
Study 25371035 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Continuous Training (MCT; sustained 60% V̇O2max)
Number of subjects: 60
Study 25371035 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL) group (no training)
Number of subjects: 60
Study 23473350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg/d for 2 weeks
Number of subjects: 240
Study 23473350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 80 mg/d for 2 weeks
Number of subjects: 240
Study 23473350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg/d for 1 week, increased to 80 mg/d on day 8 for week 2
Number of subjects: 240
Study 23473350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (flexibly dosed 40-120 mg/d for subsequent 4 weeks)
Number of subjects: 240
Study 21703067 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate (MTA)
Number of subjects: 32
Study 21703067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric sulfate (FS)
Number of subjects: 32
Study 21703067 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol (FC)
Number of subjects: 32
Study 21703067 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide eugenol (ZOE)
Number of subjects: 32
Study 19027101 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 94
Study 19027101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 17420681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cognitive-behavioral therapy (CBT) - 14 sessions of daily psychotherapy
Number of subjects: 40
Study 17420681 — intervention group
Group type: COMPARATOR
Intervention: Weekly cognitive-behavioral therapy (CBT) - 14 sessions of weekly psychotherapy
Number of subjects: 40
Study 17420681 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cognitive-behavioral therapy (CBT)
Number of subjects: 40
Study 17420681 — intervention group
Group type: COMPARATOR
Intervention: Weekly cognitive-behavioral therapy (CBT)
Number of subjects: 40
Study 17420681 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Yale‐Brown Obsessive‐Compulsive Scale
Number of subjects: 40
Study 15136305 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or severe reductions in GFR (30-59 mL/min per 1.73 m² and <29 mL/min per 1.73 m²)
Number of subjects: 40514
Study 15136305 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in GFR of 10 mL/min per 1.73 m²
Number of subjects: 40514
Study 15136305 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR of approximately 60 to 70 mL/min per 1.73 m²
Number of subjects: 40514
Study 11277132 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage and customized compression garments
Number of subjects: 11
Study 9551245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg once daily for 5 days
Number of subjects: 150
Study 9551245 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 600 mg divided into three doses for 5 days
Number of subjects: 150
Study 9551245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 200 mg once daily
Number of subjects: 150
Study 9551245 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin 600 mg divided into three doses
Number of subjects: 150
Study 7936839 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal propeptide of type III procollagen (PIIINP) concentration measured by Fab'-fragment and whole antibody-based RIA assay in cord serum and amniotic fluid
Number of subjects: 602
Study 7936839 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal propeptide of type III procollagen (PIIINP) concentration
Number of subjects: 602
Study 3215203 — intervention group
Group type: EXPERIMENTAL
Intervention: Theo-Dur Sprinkle (TDS)
Number of subjects: 8
Study 3215203 — intervention group
Group type: COMPARATOR
Intervention: Theophylline elixir
Number of subjects: 8
Study 29547234 — intervention group
Group type: EXPERIMENTAL
Intervention: KED‐XT
Number of subjects: 50
Study 29547234 — intervention group
Group type: EXPERIMENTAL
Intervention: KED
Number of subjects: 50
Study 29547234 — intervention group
Group type: COMPARATOR
Intervention: KED vs KED‐XT
Number of subjects: 50
Study 27325335 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (lower dose 7.5 mg/kg)
Number of subjects: 0
Study 24735616 — intervention group
Group type: EXPERIMENTAL
Intervention: Long inpatient multicomponent rehabilitation program (3 ½ weeks with full rehabilitation days)
Number of subjects: 0
Study 24735616 — intervention group
Group type: EXPERIMENTAL
Intervention: Short inpatient multicomponent rehabilitation program (4+4 full days, separated by two weeks)
Number of subjects: 0
Study 24735616 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient cognitive behavioral therapy group
Number of subjects: 0
Study 24735616 — intervention group
Group type: COMPARATOR
Intervention: Usual care reference group (untouched control group)
Number of subjects: 0
Study 24735616 — intervention group
Group type: EXPERIMENTAL
Intervention: Long inpatient multicomponent rehabilitation program
Number of subjects: 0
Study 24735616 — intervention group
Group type: EXPERIMENTAL
Intervention: Short inpatient multicomponent rehabilitation program
Number of subjects: 0
Study 24059292 — intervention group
Group type: EXPERIMENTAL
Intervention: AIMS intervention
Number of subjects: 230
Study 24059292 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 230
Study 20841517 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing Professional Development (CPD) workshops (3 workshops)
Number of subjects: 100
Study 20841517 — intervention group
Group type: COMPARATOR
Intervention: Traditional Continuing Pharmacy Education (CPE)
Number of subjects: 100
Study 18000691 — intervention group
Group type: EXPERIMENTAL
Intervention: Xialine
Number of subjects: 29
Study 18000691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 16042894 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily for up to 5 years
Number of subjects: 81
Study 16042894 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of lamivudine therapy after HBeAg seroconversion
Number of subjects: 81
Study 12357479 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol at high relative humidity (> 90%)
Number of subjects: 9
Study 12357479 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol at low relative humidity (13%)
Number of subjects: 9
Study 12357479 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate aerosol at intermediate relative humidity (room air)
Number of subjects: 9
Study 12357479 — intervention group
Group type: COMPARATOR
Intervention: Comparison of droplet size distributions
Number of subjects: 9
Study 10615935 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ASGB
Number of subjects: 50
Study 10615935 — intervention group
Group type: COMPARATOR
Intervention: Open ASGB
Number of subjects: 50
Study 10615935 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 7852463 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course of empiric therapy
Number of subjects: 0
Study 7852463 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to predisposing behaviors (urine retention, barrier contraception, inadequate fluid intake, poor hygiene)
Number of subjects: 0
Study 1883793 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (n = 11)
Number of subjects: 23
Study 1883793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nylidrin (n = 12)
Number of subjects: 23
Study 1883793 — intervention group
Group type: COMPARATOR
Intervention: Control group (23 pregnancies without uterine contractions)
Number of subjects: 23
Study 1883793 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth group (12 women who gave birth preterm)
Number of subjects: 23
Study 1883793 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-term labour group
Number of subjects: 23
Study 6805491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl anaesthesia
Number of subjects: 18
Study 6805491 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovar anaesthesia
Number of subjects: 18
Study 6805491 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl and Innovar anaesthesia
Number of subjects: 18
Study 31609898 — intervention group
Group type: EXPERIMENTAL
Intervention: Early cycled light
Number of subjects: 0
Study 31609898 — intervention group
Group type: COMPARATOR
Intervention: Late cycled light
Number of subjects: 0
Study 31609898 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed feeding progression
Number of subjects: 0
Study 31609898 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical feeding progression
Number of subjects: 0
Study 29402253 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component occupational rehabilitation program with added workplace intervention
Number of subjects: 0
Study 29402253 — intervention group
Group type: COMPARATOR
Intervention: In-patient occupational rehabilitation program
Number of subjects: 0
Study 26938920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (bLF) 100 mg per day
Number of subjects: 79
Study 26938920 — intervention group
Group type: COMPARATOR
Intervention: Control (milk without bLF)
Number of subjects: 79
Study 24268977 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade (metoprolol)
Number of subjects: 26
Study 21443612 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group 1 (T(1), implant diameter 4.3 mm)
Number of subjects: 26
Study 21443612 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group 2 (T(2), implant diameter 4.8 mm)
Number of subjects: 26
Study 21443612 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group 3 (T(3), implant diameter 5.5 mm)
Number of subjects: 26
Study 21443612 — intervention group
Group type: COMPARATOR
Intervention: Control group (implant diameter 3.8 mm)
Number of subjects: 26
Study 21443612 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjacent teeth
Number of subjects: 26
Study 20813541 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using phthalocyanine derivatives as photosensitizers in group L (liposomes)
Number of subjects: 16
Study 20813541 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) in group L (liposomes)
Number of subjects: 16
Study 20813541 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) in group N (nanoemulsions)
Number of subjects: 16
Study 20813541 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral tooth not treated with PDT)
Number of subjects: 16
Study 17003366 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin with dexrazoxane (high-risk patients)
Number of subjects: 491
Study 17003366 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin without dexrazoxane (high-risk patients)
Number of subjects: 491
Study 17003366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive intrathecal chemotherapy (standard-risk patients)
Number of subjects: 491
Study 17003366 — intervention group
Group type: COMPARATOR
Intervention: Cranial radiation (standard-risk patients)
Number of subjects: 491
Study 17003366 — intervention group
Group type: EXPERIMENTAL
Intervention: Erwinia asparaginase (all patients)
Number of subjects: 491
Study 17003366 — intervention group
Group type: COMPARATOR
Intervention: E. coli asparaginase (all patients)
Number of subjects: 491
Study 16506860 — intervention group
Group type: EXPERIMENTAL
Intervention: INT (2 x 15 min.d(‐1) exercise program)
Number of subjects: 37
Study 16506860 — intervention group
Group type: COMPARATOR
Intervention: CON (1 x 30 min.d(‐1) exercise program)
Number of subjects: 37
Study 14636505 — intervention group
Group type: EXPERIMENTAL
Intervention: PEPAF intervention (physical activity plan designed by doctors)
Number of subjects: 7000
Study 14636505 — intervention group
Group type: COMPARATOR
Intervention: Control group (no systematic intervention on exercise until after 2005)
Number of subjects: 7000
Study 14636505 — intervention group
Group type: EXPERIMENTAL
Intervention: PEPAF intervention
Number of subjects: 7000
Study 10946879 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg, twice daily)
Number of subjects: 20
Study 10946879 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 20
Study 10946879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8833204 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoporotic patients
Number of subjects: 0
Study 8833204 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 1468460 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway pressure monitor
Number of subjects: 10
Study 1468460 — intervention group
Group type: COMPARATOR
Intervention: MR10 respiration monitor
Number of subjects: 10
Study 6388586 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 12
Study 6388586 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 12
Study 29677227 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Graft (CTG)
Number of subjects: 24
Study 29677227 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen Matrix (CM)
Number of subjects: 24
Study 29677227 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 24
Study 29926787 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash-tip catheter (SurFlash Plus, Terumo Medical Corporation)
Number of subjects: 600
Study 29926787 — intervention group
Group type: COMPARATOR
Intervention: Control catheter (Insyte Autoguard; Becton, Dickinson and Company)
Number of subjects: 600
Study 27144955 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and Plyometric Training (BPT)
Number of subjects: 24
Study 27144955 — intervention group
Group type: COMPARATOR
Intervention: Plyometric and Balance Training (PBT)
Number of subjects: 24
Study 24474180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 1.0 mL (Group A)
Number of subjects: 60
Study 24474180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 0.8 mL (Group B)
Number of subjects: 60
Study 24474180 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine 0.6 mL (Group C)
Number of subjects: 60
Study 24474180 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 60
Study 22350323 — intervention group
Group type: EXPERIMENTAL
Intervention: Maoto
Number of subjects: 28
Study 22350323 — intervention group
Group type: COMPARATOR
Intervention: Oseltamivir
Number of subjects: 28
Study 22350323 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 28
Study 20308670 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab with chemotherapy (EC-T[X])
Number of subjects: 445
Study 20308670 — intervention group
Group type: COMPARATOR
Intervention: Reference group (HER2-negative tumors treated with the same chemotherapy without trastuzumab)
Number of subjects: 445
Study 17296641 — intervention group
Group type: EXPERIMENTAL
Intervention: MINO (portable nitric oxide analyzer)
Number of subjects: 151
Study 17296641 — intervention group
Group type: COMPARATOR
Intervention: NIOX (laboratory-based analyzer)
Number of subjects: 151
Study 16119520 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabic version of the Zung Self-Rating Depression Scale
Number of subjects: 240
Study 16119520 — intervention group
Group type: COMPARATOR
Intervention: English version of the Zung Self-Rating Depression Scale
Number of subjects: 240
Study 12100089 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sumatriptan
Number of subjects: 16
Study 12100089 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rizatriptan
Number of subjects: 16
Study 12100089 — intervention group
Group type: COMPARATOR
Intervention: 20 mg temazepam
Number of subjects: 16
Study 10396791 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release morphine
Number of subjects: 48
Study 10396791 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 48
Study 10396791 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 7485936 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA + C (continuous infusion of morphine 1 mg/hr)
Number of subjects: 96
Study 7485936 — intervention group
Group type: COMPARATOR
Intervention: PCA (normal saline infusion)
Number of subjects: 96
Study 7485936 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA + C
Number of subjects: 96
Study 7485936 — intervention group
Group type: COMPARATOR
Intervention: PCA
Number of subjects: 96
Study 2290601 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic diosmin
Number of subjects: 120
Study 2290601 — intervention group
Group type: COMPARATOR
Intervention: Non-treated cases
Number of subjects: 120
Study 6179738 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 msec white noise pips at intensities ranging from 55 to 115 dB SPL
Number of subjects: 3
Study 6179738 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention conditions (counting stimuli, ignoring stimuli, visual search task)
Number of subjects: 3
Study 6179738 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus intensity of 80 to 110 dB with a probability of 0.25 for 110 dB
Number of subjects: 3
Study 6179738 — intervention group
Group type: EXPERIMENTAL
Intervention: 115 dB noise pips presented at random intervals between 10 and 90 sec
Number of subjects: 3
Study 30252061 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAU 400 mg
Number of subjects: 100
Study 30252061 — intervention group
Group type: COMPARATOR
Intervention: Control 400 mg
Number of subjects: 100
Study 30252061 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAU (various doses: 0, 100, 200, 400 mg)
Number of subjects: 100
Study 30252061 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAU
Number of subjects: 100
Study 28511660 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg once daily for up to 28 days)
Number of subjects: 540
Study 28511660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tablets for up to 28 days)
Number of subjects: 540
Study 26091830 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.50% (30 cc) + placebo
Number of subjects: 80
Study 26091830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.50% (30 cc) + dexmedetomidine 1 μg/kg
Number of subjects: 80
Study 24834935 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (PCV)
Number of subjects: 109
Study 22496101 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Losec MUPS for a period of 2 months
Number of subjects: 40
Study 22496101 — intervention group
Group type: COMPARATOR
Intervention: Low-dose vitamin C tablet for a period of 2 months
Number of subjects: 40
Study 22496101 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between the two groups
Number of subjects: 40
Study 19327949 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia group (n = 20)
Number of subjects: 40
Study 19327949 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia group (n = 20)
Number of subjects: 40
Study 19327949 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40